Changeflow GovPing

What do you monitor?

Curated feeds for your role. Pick your area and get exactly the sources you need.

Recent changes

Favicon for changeflow.com

Hispidin Derivative Synthesis Method and Use

The USPTO has published a patent application (US20260085054A1) detailing a new method for synthesizing Hispidin derivatives and their use in preparing lipid-lowering drugs. The application describes a process using readily available starting materials with potential for large-scale industrial application.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application for Benzofuran Derivatives as SIK Inhibitors

The USPTO has published a patent application (US20260085053A1) from BEONE MEDICINES I GMBH for benzofuran derivatives that act as SIK inhibitors. These compounds are intended for the treatment of various inflammatory diseases.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application for Furan Derivative Oxidation Process

The USPTO has published a patent application (US20260085052A1) detailing a new process for producing 2,5-furandicarboxylic acid. The application, filed by David Lee Sikkenga and Jan Hendrik Blank, describes a specific oxidation method involving furan derivatives, oxidants, solvents, and catalysts.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application for 2-Chloro-4-Fluoro-5-Nitrobenzoic Acid Preparation

The USPTO has published a patent application (US20260085051A1) detailing a novel nitration process for preparing 2-chloro-4-fluoro-5-nitrobenzoic acid. The assignee is ADAMA AGAN LTD. This compound is used in the synthesis of the herbicide saflufenacil.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Triple Kinase Inhibitors for Cancer Treatment

The USPTO has published a patent application (US20260085050A1) for triple kinase inhibitor compounds designed for cancer treatment. The application details compounds that inhibit EGFR, ALK, and MET simultaneously, along with methods for treating cancer using these inhibitors.

Routine Guidance Pharmaceuticals
Favicon for changeflow.com

Ergothioneine Crystal Form Patent Application

The USPTO has published a patent application (US20260085049A1) for a novel crystal form of ergothioneine and its preparation method. The application details a method for producing high-purity ergothioneine with low moisture content, intended for use in dietary supplements, foods, and cosmetics.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

ACSS2 Inhibitors for Cancer, Alcoholism, Viral Infections

The USPTO has published a patent application (US20260085048A1) detailing novel ACSS2 inhibitors and their potential uses in treating cancer, alcoholism, and viral infections. The application was filed on September 8, 2025.

Routine Guidance Pharmaceuticals
Favicon for changeflow.com

Triphenylazole Compound Patent Application for Synucleinopathy Treatment

The USPTO has published a patent application (US20260085047A1) filed by Shiratori Pharmaceutical Co., Ltd. for a triphenylazole compound intended for the treatment or prevention of synucleinopathy. The application details the compound's structure and its potential use in pharmaceutical compositions.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application: Dual Function Compounds for Cancer Treatment

The USPTO has published patent application US20260085046A1, filed on August 7, 2025, for dual function compounds intended for cancer treatment. The application discloses compounds of Formula (I) and their use in treating cancer.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application for Nitrogen-Containing Heterocyclic Derivative Inhibitor

The USPTO has published a patent application (US20260085045A1) for a nitrogen-containing heterocyclic derivative inhibitor. The application details a compound, its preparation method, and its use in treating diseases such as cardiovascular and cerebrovascular conditions.

Routine Notice Pharmaceuticals

Showing 12381–12390 of 39,113 changes

1 1237 1238 1239 1240 1241 3912

Get alerts when regulations change

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.